Idasal

Xylometazoline Hydrochloride, the active ingredient in Idasal, is an imidazoline nasal decongestant presented as a nasal spray for intranasal use. It relieves nasal congestion associated with the common cold, sinusitis and allergic rhinitis in adults and children. GNH USA supplies Idasal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Idasal, an imidazoline nasal decongestant, is used to alleviate congestion in upper‑respiratory conditions.

- Common cold: reduces nasal blockage and improves breathing. - Sinusitis: decreases mucosal swelling to aid sinus drainage. - Allergic rhinitis: alleviates congestion caused by allergen‑induced inflammation.

Adverse reactions may occur with intranasal use of Xylometazoline Hydrochloride.

Common Side Effects: - Nasal irritation or burning sensation. - Sneezing or mild itching. - Dryness of the nasal mucosa. - Transient headache. - Bitter taste after administration.

Serious or Rare Side Effects: - Persistent nasal congestion (rebound congestion) after prolonged use. - Hypertension or elevated blood pressure. - Tachycardia or irregular heart rhythm. - Severe allergic reaction (rash, swelling, difficulty breathing).

Before using Idasal, consider the following safety measures.

- Duration of use: limit to no more than 3‑5 consecutive days to avoid rebound congestion. - Underlying conditions: avoid if you have uncontrolled hypertension, coronary artery disease, or hyperthyroidism. - Pregnancy and lactation: consult a healthcare professional before use, as safety data are limited. - Pediatric use: follow age‑specific recommendations provided by the prescriber. - Drug interactions: inform your clinician of any concurrent sympathomimetic or MAO‑inhibitor therapy. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Xylometazoline may interact with other agents that affect the sympathetic nervous system.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of excessive vasoconstriction and hypertension. - Other topical nasal decongestants: additive vasoconstrictive effect leading to rebound congestion. - Tricyclic antidepressants: may potentiate cardiovascular stimulation.

Moderate Interactions (Monitor Closely): - Beta‑blockers: possible attenuation of decongestant effect on blood pressure. - Antihypertensive agents: monitor for unexpected blood pressure changes. - Phosphodiesterase‑5 inhibitors: watch for synergistic cardiovascular effects.